v3.26.1
Cash Equivalents and Marketable Securities
12 Months Ended
Dec. 31, 2025
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Marketable Securities

4. Cash Equivalents and Marketable Securities

Cash equivalents and marketable securities consisted of the following:

 

 

December 31, 2025

 

 

 

Amortized
Cost Basis

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

 

 

(in thousands)

 

Money market funds

 

$

51,333

 

 

$

 

 

$

 

 

$

51,333

 

Commercial paper

 

 

29,134

 

 

 

5

 

 

 

 

 

 

29,139

 

Corporate debt securities

 

 

16,950

 

 

 

2

 

 

 

 

 

 

16,952

 

Asset-based securities

 

 

7,281

 

 

 

 

 

 

(1

)

 

 

7,280

 

U.S. government securities

 

 

29,914

 

 

 

13

 

 

 

 

 

 

29,927

 

Total

 

 

134,612

 

 

 

20

 

 

 

(1

)

 

 

134,631

 

Less: amounts classified as cash equivalents

 

 

(51,333

)

 

 

 

 

 

 

 

 

(51,333

)

Total marketable securities

 

$

83,279

 

 

$

20

 

 

$

(1

)

 

$

83,298

 

 

 

 

December 31, 2024

 

 

 

Amortized
Cost Basis

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

 

(in thousands)

 

Money market funds

 

$

68,474

 

 

$

 

 

$

 

 

$

68,474

 

Commercial paper

 

 

50,933

 

 

 

3

 

 

 

(4

)

 

 

50,932

 

Corporate debt securities

 

 

94,248

 

 

 

13

 

 

 

(4

)

 

 

94,257

 

Asset-based securities

 

 

40,521

 

 

 

2

 

 

 

(1

)

 

 

40,522

 

U.S. government securities

 

 

49,619

 

 

 

25

 

 

 

 

 

 

49,644

 

U.S. agency securities

 

 

9,577

 

 

 

5

 

 

 

 

 

 

9,582

 

Total

 

 

313,372

 

 

 

48

 

 

 

(9

)

 

 

313,411

 

Less: amounts classified as cash equivalents

 

 

(186,818

)

 

 

(9

)

 

 

7

 

 

 

(186,820

)

Total marketable securities

 

$

126,554

 

 

$

39

 

 

$

(2

)

 

$

126,591

 

No marketable securities had maturities of more than one year as of December 31, 2025 and 2024.

During the years ended December 31, 2025 and 2024, the Company did not record any other-than-temporary impairment charges on its available-for-sale securities. Based on the Company’s procedures under the expected credit loss model, including an assessment of unrealized losses on the portfolio after December 31, 2025, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of December 31, 2025. Also, based on the scheduled maturities of the investments, the Company was more likely than not to hold these investments for a period of time sufficient for a recovery of the Company’s cost basis.

The Company recognized no material gains or losses on its cash equivalents and current marketable securities as of December 31, 2025 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income (loss) for the year then ended.